Royalty Pharma plc, founded in 1996 and headquartered in New York City, is a leading buyer of royalty interests in innovative biopharmaceutical products. The company aims to provide investors with access to diverse, revenue-generating assets from established therapies and promising late-stage product candidates. Royalty Pharma's portfolio includes royalties from major pharmaceuticals such as AbbVie’s Imbruvica and Vertex's cystic fibrosis treatments, illustrating its strategic focus on high-value healthcare investments.
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Since its inception, Royalty Pharma has established itself in the bond market, particularly with significant issuances starting in 2020 when it raised $2 billion in a multi-tranche offering. Recently, the company issued bonds to finance acquisitions, reflecting its aggressive growth strategy and aim to enhance its royalty portfolio. Current yields on its bonds are competitive compared to the healthcare sector, with the latest offering in 2023 attracting considerable interest due to its favorable terms, which may include call features that provide investors flexibility amidst varying market conditions.